Development of Novel β-Carboline/Furylmalononitrile Hybrids as Type I/II Photosensitizers with Chemo-Photodynamic Therapy and Minimal Toxicity-Reference-Cited by-同舟云学术

Development of Novel β-Carboline/Furylmalononitrile Hybrids as Type I/II Photosensitizers with Chemo-Photodynamic Therapy and Minimal Toxicity

Published:2024-05-31 Issue:7 Volume:21 Page:3553-3565
ISSN:1543-8384
Container-title:Molecular Pharmaceutics
language:en
Short-container-title:Mol. Pharmaceutics

Author:

Xie Xudong¹²,Sun Tiantian²,Pan Heyu¹²,Ji Dongliang¹²,Xu Zhongyuan²,Gao Ge¹²,Miao Jiefei¹³,Wang Lei²,Zhang Yanan²,Liu Ji¹²,Ling Yong¹²^ORCID,Su Xing¹²

Affiliation:

1. Department of Pharmacy, Department of Neurosurgery, Affiliated Hospital of Nantong University, Nantong 226001, China

2. School of Pharmacy and Jiangsu Province Key Laboratory for Inflammation and Molecular Drug Target, Nantong Key Laboratory of Small Molecular Drug Innovation, Nantong University, Nantong 226001, China

3. Department of Oncology, Affiliated Hospital of Nantong University, Nantong 226001, China

Funder

Jiangsu Provincial Key Research and Development Program

Natural Science Research of Jiangsu Higher Education Institutions of China

Graduate Research and Innovation Projects of Jiangsu Province

China Postdoctoral Science Foundation

National Natural Science Foundation of China

Publisher

American Chemical Society (ACS)

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.molpharmaceut.4c00238

Reference49 articles.

1. Cancer Burden in China during 1990–2019: Analysis of the Global Burden of Disease

2. Ferroptosis-based drug delivery system as a new therapeutic opportunity for brain tumors

3. Sequentially self-assembled polysaccharide-based nanocomplexes for combined chemotherapy and photodynamic therapy of breast cancer

4. Light-Activated Monomethyl Auristatin E Prodrug Nanoparticles for Combinational Photo-Chemotherapy of Pancreatic Cancer

5. Addressing Drug Resistance in Cancer with Macromolecular Chemotherapeutic Agents